Nektar Therapeutics' data update for the up-and-coming immuno-oncology candidate NKTR-214 – just partnered in a high-priced deal with Bristol-Myers Squibb Co. – along with better-than-expected earnings revved up even more excitement and expectations among investors.
The company's fourth quarter and full year 2017 earnings call late on March 1 followed on the heels of a deal with Bristol to co-develop and commercialize the pegylated IL-2 agonist NKTR-214 in combination with Bristol's PD-1 inhibitor Opdivo (nivolumab) and CTLA-4 inhibitor Yervoy (ipilimumab), an agreement worth $1.85bn upfront plus $1.78bn in milestone fees. Also see "Bristol Goes In Big On New Valentine Nektar" - Scrip, 14 February, 2018
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?